These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9237497)

  • 21. Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family.
    Serfas KD; Bose D; Patel L; Wrogemann K; Phillips MS; MacLennan DH; Greenberg CR
    Anesthesiology; 1996 Feb; 84(2):322-9. PubMed ID: 8602662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine- and the ryanodine-contracture-test results in MH susceptible, normal and control muscle.
    Hartung E; Koob M; Anetseder M; Schoemig P; Krauspe R; Hogrefe G; Engelhardt W
    Acta Anaesthesiol Scand; 1996 Apr; 40(4):437-44. PubMed ID: 8738688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of a novel RYR1 mutation in four malignant hyperthermia pedigrees.
    Keating KE; Quane KA; Manning BM; Lehane M; Hartung E; Censier K; Urwyler A; Klausnitzer M; Muller CR; Heffron JJ
    Hum Mol Genet; 1994 Oct; 3(10):1855-8. PubMed ID: 7849712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: novel mutations and concordance with the in vitro contracture test.
    Brandt A; Schleithoff L; Jurkat-Rott K; Klingler W; Baur C; Lehmann-Horn F
    Hum Mol Genet; 1999 Oct; 8(11):2055-62. PubMed ID: 10484775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility.
    Monnier N; Kozak-Ribbens G; Krivosic-Horber R; Nivoche Y; Qi D; Kraev N; Loke J; Sharma P; Tegazzin V; Figarella-Branger D; Roméro N; Mezin P; Bendahan D; Payen JF; Depret T; Maclennan DH; Lunardi J
    Hum Mutat; 2005 Nov; 26(5):413-25. PubMed ID: 16163667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exclusion of defects in the skeletal muscle specific regions of the DHPR alpha 1 subunit as frequent causes of malignant hyperthermia.
    O'Brien RO; Taske NL; Hansbro PM; Matthaei KI; Hogan SP; Denborough MA; Foster PS
    J Med Genet; 1995 Nov; 32(11):913-4. PubMed ID: 8592342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patients with malignant hyperthermia demonstrate an altered calcium control mechanism in B lymphocytes.
    Sei Y; Brandom BW; Bina S; Hosoi E; Gallagher KL; Wyre HW; Pudimat PA; Holman SJ; Venzon DJ; Daly JW; Muldoon S
    Anesthesiology; 2002 Nov; 97(5):1052-8. PubMed ID: 12411786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phenotyping malignant hyperthermia susceptibility by measuring halothane-induced changes in myoplasmic calcium concentration in cultured human skeletal muscle cells.
    Girard T; Treves S; Censier K; Mueller CR; Zorzato F; Urwyler A
    Br J Anaesth; 2002 Oct; 89(4):571-9. PubMed ID: 12393358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Caffeine and halothane sensitivity of intracellular Ca2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease.
    Tong J; Oyamada H; Demaurex N; Grinstein S; McCarthy TV; MacLennan DH
    J Biol Chem; 1997 Oct; 272(42):26332-9. PubMed ID: 9334205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional characterization of the RYR1 mutation p.Arg4737Trp associated with susceptibility to malignant hyperthermia.
    Johannsen S; Treves S; Müller CR; Mögele S; Schneiderbanger D; Roewer N; Schuster F
    Neuromuscul Disord; 2016 Jan; 26(1):21-5. PubMed ID: 26631338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discordance between malignant hyperthermia susceptibility and RYR1 mutation C1840T in two Scandinavian MH families exhibiting this mutation.
    Fagerlund TH; Ording H; Bendixen D; Islander G; Ranklev Twetman E; Berg K
    Clin Genet; 1997 Dec; 52(6):416-21. PubMed ID: 9520251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of heterozygous and homozygous individuals with the novel RYR1 mutation Cys35Arg in a large kindred.
    Lynch PJ; Krivosic-Horber R; Reyford H; Monnier N; Quane K; Adnet P; Haudecoeur G; Krivosic I; McCarthy T; Lunardi J
    Anesthesiology; 1997 Mar; 86(3):620-6. PubMed ID: 9066328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ryanodine receptor type 1 gene variants in the malignant hyperthermia-susceptible population of the United States.
    Brandom BW; Bina S; Wong CA; Wallace T; Visoiu M; Isackson PJ; Vladutiu GD; Sambuughin N; Muldoon SM
    Anesth Analg; 2013 May; 116(5):1078-1086. PubMed ID: 23558838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of a novel common mutation in the ryanodine receptor gene in malignant hyperthermia: implications for diagnosis and heterogeneity studies.
    Quane KA; Keating KE; Manning BM; Healy JM; Monsieurs K; Heffron JJ; Lehane M; Heytens L; Krivosic-Horber R; Adnet P
    Hum Mol Genet; 1994 Mar; 3(3):471-6. PubMed ID: 8012359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Diagnosis of malignant hyperthermia susceptibility. 1. The significance of in vitro susceptibility tests].
    Mortier W; Breucking E
    Anaesthesist; 1993 Oct; 42(10):675-83. PubMed ID: 8250201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional characterization of malignant hyperthermia-associated RyR1 mutations in exon 44, using the human myotube model.
    Wehner M; Rueffert H; Koenig F; Olthoff D
    Neuromuscul Disord; 2004 Jul; 14(7):429-37. PubMed ID: 15210166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discordance, in a malignant hyperthermia pedigree, between in vitro contracture-test phenotypes and haplotypes for the MHS1 region on chromosome 19q12-13.2, comprising the C1840T transition in the RYR1 gene.
    Deufel T; Sudbrak R; Feist Y; Rübsam B; Du Chesne I; Schäfer KL; Roewer N; Grimm T; Lehmann-Horn F; Hartung EJ
    Am J Hum Genet; 1995 Jun; 56(6):1334-42. PubMed ID: 7762556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mild clinical and histopathological features in patients who carry the frequent and causative malignant hyperthermia RyR1 mutation p.Thr2206Met.
    Rueffert H; Wehner M; Ogunlade V; Meinecke C; Schober R
    Clin Neuropathol; 2009; 28(6):409-16. PubMed ID: 19919814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional and genetic characterization of clinical malignant hyperthermia crises: a multi-centre study.
    Klingler W; Heiderich S; Girard T; Gravino E; Heffron JJ; Johannsen S; Jurkat-Rott K; Rüffert H; Schuster F; Snoeck M; Sorrentino V; Tegazzin V; Lehmann-Horn F
    Orphanet J Rare Dis; 2014 Jan; 9():8. PubMed ID: 24433488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genotype-phenotype comparison of the Swiss malignant hyperthermia population.
    Girard T; Urwyler A; Censier K; Mueller CR; Zorzato F; Treves S
    Hum Mutat; 2001 Oct; 18(4):357-8. PubMed ID: 11668625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.